H.C. Wainwright Keeps Their Buy Rating on Acer Therapeutics Inc (ACER)


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Acer Therapeutics Inc (ACER) today and set a price target of $55. The company’s shares closed on Friday at $18.75, close to its 52-week low of $16.02.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -3.0% and a 29.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Acer Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $53, representing a 182.7% upside. In a report issued on May 22, Wedbush also initiated coverage with a Buy rating on the stock with a $48 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $34.10 and a one-year low of $16.02. Currently, Acer Therapeutics Inc has an average volume of 53.55K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts